Switch theme
Sign up to access all valuation multiples
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
2007
89
LTM Revenue $23.5M
LTM EBITDA n/a
$27.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aadi Bioscience has a last 12-month revenue of $23.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aadi Bioscience achieved revenue of $24.4M and an EBITDA of -$65.4M.
Aadi Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aadi Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $24.4M | $25.9M | XXX | XXX | XXX |
| Gross Profit | n/a | $13.9M | XXX | XXX | XXX |
| Gross Margin | NaN% | 54% | XXX | XXX | XXX |
| EBITDA | -$65.4M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -268% | NaN% | XXX | XXX | XXX |
| Net Profit | -$110M | -$60.5M | XXX | XXX | XXX |
| Net Margin | -452% | -234% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Aadi Bioscience's stock price is $2.
Aadi Bioscience has current market cap of $89.3M, and EV of $27.7M.
See Aadi Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $27.7M | $89.3M | XXX | XXX | XXX | XXX | $-1.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Aadi Bioscience has market cap of $89.3M and EV of $27.7M.
Aadi Bioscience's trades at 1.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Aadi Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aadi Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $27.7M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAadi Bioscience's NTM/LTM revenue growth is -40%
Aadi Bioscience's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Aadi Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aadi Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aadi Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 201% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 384% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aadi Bioscience acquired XXX companies to date.
Last acquisition by Aadi Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Aadi Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aadi Bioscience founded? | Aadi Bioscience was founded in 2007. |
| Where is Aadi Bioscience headquartered? | Aadi Bioscience is headquartered in United States of America. |
| How many employees does Aadi Bioscience have? | As of today, Aadi Bioscience has 89 employees. |
| Who is the CEO of Aadi Bioscience? | Aadi Bioscience's CEO is Dr. David James Lennon, PhD. |
| Is Aadi Bioscience publicy listed? | Yes, Aadi Bioscience is a public company listed on NAS. |
| What is the stock symbol of Aadi Bioscience? | Aadi Bioscience trades under AADI ticker. |
| When did Aadi Bioscience go public? | Aadi Bioscience went public in 2021. |
| Who are competitors of Aadi Bioscience? | Similar companies to Aadi Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aadi Bioscience? | Aadi Bioscience's current market cap is $89.3M |
| What is the current revenue of Aadi Bioscience? | Aadi Bioscience's last 12-month revenue is $23.5M. |
| What is the current EV/Revenue multiple of Aadi Bioscience? | Current revenue multiple of Aadi Bioscience is 1.2x. |
| What is the current revenue growth of Aadi Bioscience? | Aadi Bioscience revenue growth between 2023 and 2024 was 6%. |
| Is Aadi Bioscience profitable? | Yes, Aadi Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
